A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Samsung Seoul Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be willing and able to provide written informed consent.
- BMI of < 35 kg/m2
- Patients experiencing one or more of functional dyspepsia symptoms beginning at least 6 months prior according to Rome III criteria, with the symptom(s) evident over the last 3 months at the time of screening
- Patients with no evidence of organic lesions based on upper GI endoscopy, which could be the cause of dyspeptic symptoms
- Women of childbearing potential (WOCBP) must have a negative pregnancy test result at the screening visit and use an adequate method of contraception to avoid pregnancy throughout the study
Exclusion Criteria:
- Women who are pregnant or breastfeeding.
- Women with a positive pregnancy test result on enrollment or prior to investigational product administration.
- Subjects with a history of surgery that could affect gastrointestinal motility
- Subjects with inflammatory bowel disease
- Clinically significant chronic infection (eg. AIDS, etc), or significant medical or psychiatric illness.
- Serious cardiovascular disease (including QT prolongation defined as QTc interval ≥ 450msec) or respiratory disease
- History of alcohol or drug abuse within the previous one year.
- Subjects with mental illness (e.g. schizophrenia, dementia etc) that may render the inability to complete the study
- Physical and Laboratory Test Findings
- Administration of any other investigational product or participation in other clinical trials within 3 months prior to randomization.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: YH12852 0.1 mg
twice daily for 4 weeks
|
|
|
Experimental: YH12852 0.25 mg
twice daily for 4 weeks
|
|
|
Experimental: YH12852 0.5 mg
twice daily for 4 weeks
|
|
|
Placebo Comparator: Placebo
twice daily for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ratio of OTE (Overall Treatment Efficacy) responders
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Ratio of OSS responders
Time Frame: 4 weeks
|
4 weeks
|
|
Elimination rate for 8 functional dyspepsia symptoms
Time Frame: 4 weeks
|
4 weeks
|
|
Change from basline in NDI QoL score
Time Frame: 4 weeks
|
4 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Poong Lyul Lee, MD, Ph.D, Samsung Seoul Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- YH12852-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.